CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities
-
December 13 2018
-
-
Source: Ophthalmic Epidemiol. 2019; 26(1):1-6
Details:
-
Alternative Title:Ophthalmic Epidemiol
-
Personal Author:
-
Description:Trachoma, caused by repeated ocular infection with Chlamydia trachomatis, is the leading infectious cause of blindness worldwide and is targeted for elimination as a public health problem. We sought to determine whether a one-time azithromycin mass treatment would reduce trachomatous inflammation-follicular (TF) levels below the elimination threshold of 5% in communities with disease prevalence between 5 and 9.9%.|The study was conducted in 96 sub-village units (balozis) in the Kongwa district of Tanzania which were predicted from prior prevalence surveys to have TF between 5 and 9.9%. Balozis were randomly assigned to the intervention and control arms. The intervention arm received a single mass drug administration of azithromycin. At baseline and 12-month follow-up, ocular exams for trachoma, ocular swabs for detection of chlamydial DNA, and finger prick blood for analysis of anti-chlamydial antibody were taken.|Comparison of baseline and 12-month follow-up showed no significant difference in the overall TF| prevalence by balozi between control and treatment arms. In the treatment arm there was a significant reduction of ocular infection 12 months after treatment (p = 0.004) but no change in the control arm. No change in Pgp3-specific antibody responses were observed after treatment in the control or treatment arms. Anti-CT694 responses increased in both study arms (p = 0.009 for control arm and p = 0.04 for treatment arm).|These data suggest that a single round of MDA may not be sufficient to decrease TF levels below 5% when TF| is between 5 and 9.9% at baseline.
-
Subjects:
-
Source:
-
Pubmed ID:30543311
-
Pubmed Central ID:PMC6352373
-
Document Type:
-
Place as Subject:
-
Volume:26
-
Issue:1
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: